New Combination Therapy Shows Promise for Advanced Lung Cancer
A recent clinical trial conducted by researchers at the Abramson Family Cancer Center at the University of Pennsylvania Perelman School of Medicine has demonstrated the potential of a novel combination therapy for advanced lung cancer . The study, published in Science, explored the effects of combining an anti-inflammatory drug with anti-PD1 checkpoint inhibitor immunotherapy. This innovative approach targets the dual nature of inflammation, which can both combat infections and cancers in the short term and, when chronic, suppress the immune system. The trial involved 21 patients with advanced non-small cell lung cancer (NSCLC) who were treated with a JAK1 inhibitor. This drug reduces persistent inflammatory signaling without affecting the initial inflammation necessary for antitumor activity. After receiving two doses of anti-PD1 immunotherapy, patients were administered the JAK1 inhibitor for six weeks. The results were impressive, with a 67 percent overall response rate a...